TD Asset Management Inc Buys 129,248 Shares of Arcellx, Inc. $ACLX

TD Asset Management Inc lifted its position in Arcellx, Inc. (NASDAQ:ACLX) by 124.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 232,708 shares of the company’s stock after purchasing an additional 129,248 shares during the period. TD Asset Management Inc owned about 0.40% of Arcellx worth $19,105,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ACLX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Arcellx by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,753 shares of the company’s stock worth $1,893,000 after purchasing an additional 1,390 shares during the last quarter. Empowered Funds LLC bought a new stake in shares of Arcellx in the 1st quarter worth approximately $1,768,000. Intech Investment Management LLC increased its stake in shares of Arcellx by 27.7% during the first quarter. Intech Investment Management LLC now owns 21,967 shares of the company’s stock valued at $1,441,000 after buying an additional 4,760 shares during the period. Teacher Retirement System of Texas raised its holdings in shares of Arcellx by 1.7% during the second quarter. Teacher Retirement System of Texas now owns 8,883 shares of the company’s stock valued at $585,000 after acquiring an additional 151 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Arcellx in the second quarter worth $563,000. 96.03% of the stock is currently owned by institutional investors.

Insider Transactions at Arcellx

In other news, insider Christopher Heery sold 7,437 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $65.51, for a total transaction of $487,197.87. Following the sale, the insider owned 29,631 shares in the company, valued at $1,941,126.81. This represents a 20.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Rami Elghandour sold 89,916 shares of the stock in a transaction on Friday, February 27th. The shares were sold at an average price of $113.92, for a total value of $10,243,230.72. Following the sale, the insider owned 276,051 shares in the company, valued at approximately $31,447,729.92. This represents a 24.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 109,366 shares of company stock worth $11,526,708. 8.35% of the stock is currently owned by company insiders.

Key Arcellx News

Here are the key news stories impacting Arcellx this week:

• Neutral Sentiment: Reported short-interest data shows zero shares and a 0.0 days-to-cover figure for late February; this looks like a data or reporting anomaly rather than a meaningful change in market positioning — monitor for corrected filings or confirmations from exchanges.
• Neutral Sentiment: HC Wainwright published an FY2030 earnings forecast for Arcellx; long-range model updates can influence valuation assumptions but are less likely to move the stock immediately than near-term operational news. FY2030 Earnings Forecast for Arcellx Issued By HC Wainwright
• Neutral Sentiment: Market commentary pieces (example: “Is It Too Late To Consider Arcellx…”) are evaluating the recent run-up and valuation; these are background reads that may sway retail interest but do not constitute new company fundamentals. Is It Too Late To Consider Arcellx (ACLX) After Its Recent Share Price Surge?
• Negative Sentiment: Insider selling: Director Rami Elghandour sold 89,916 shares at ~$113.92 (≈$10.24M), cutting his stake by ~24.6%. Large insider sales at current levels can weigh on sentiment, especially after a recent price run. SEC Filing
• Negative Sentiment: Quarterly results: ACLX reported EPS of ($1.01), matching consensus, but revenue was $1.65M vs. expectations of $13.4M — a sizable revenue shortfall that highlights execution or timing risk and likely increases near-term volatility and downside pressure.
• Negative Sentiment: Analyst actions: UBS downgraded the stock, and both Robert W. Baird and Canaccord Genuity moved ACLX to “Hold” — multiple downward analyst moves reduce buy-side momentum and can trigger short-term selling. UBS downgrades Arcellx (ACLX) Cut to Hold at Robert W. Baird Cut to Hold at Canaccord Genuity Group

Arcellx Stock Down 0.1%

ACLX stock opened at $113.79 on Friday. The business has a 50 day moving average of $71.81 and a 200 day moving average of $76.25. Arcellx, Inc. has a twelve month low of $47.86 and a twelve month high of $114.26. The firm has a market cap of $6.58 billion, a PE ratio of -28.95 and a beta of 0.36.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Robert W. Baird reaffirmed a “neutral” rating and issued a $115.00 target price (up from $106.00) on shares of Arcellx in a research report on Monday, February 23rd. Wells Fargo & Company lowered shares of Arcellx from an “overweight” rating to an “equal weight” rating and set a $115.00 price objective for the company. in a report on Monday, February 23rd. Leerink Partners reaffirmed a “market perform” rating and set a $115.00 price objective on shares of Arcellx in a research report on Tuesday, February 24th. Evercore set a $115.00 target price on Arcellx in a research report on Monday, February 23rd. Finally, Guggenheim cut Arcellx from a “buy” rating to a “neutral” rating and lowered their target price for the company from $120.00 to $115.00 in a research note on Wednesday. One equities research analyst has rated the stock with a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Arcellx currently has a consensus rating of “Hold” and a consensus target price of $111.87.

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.